As opposed to MET alterations, ALK fusions represent a well-established therapeutic target in lung cancer, as they are detected in 3–7% of NSCLCs and have been associated with an absence of smoking, younger age, and adenocarcinoma histology [26]. The gene discussed is MET; the disease is lung cancer.